SCHEMBL5015382

SCHEMBL5015382

CC/C=C\CCC(=O)NC1CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 4/20 0.71
▸ CNR1 P21554 2/20 0.71
▸ ALDH1A1 P00352 7/20 0.58
▸ MAPT P10636 3/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ HPGD P15428 1/20 0.58
▸ FAAH O00519 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CYP19A1 P11511 2/20 0.44
▸ RXRA P19793 2/20 0.44
▸ PPARG P37231 2/20 0.44
▸ OXER1 Q8TDS5 2/20 0.44
▸ FFAR1 O14842 1/20 0.44
▸ SMYD3 Q9H7B4 1/20 0.42
▸ F7 P08709 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ F3 P13726 1/20 0.42
▸ PTGS1 P23219 1/20 0.42
▸ PPARD Q03181 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5015349 1.00 CNR2 (0.71) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL15606927 0.89 CNR2 (0.71) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL15526152 0.89 CNR2 (0.71) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL22315788 0.85 CNR2 (0.74) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL12555962 0.85 ALDH1A1 (0.81) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL5016654 0.84 MAPT (0.80) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL5016615 0.84 MAPT (0.80) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL22315786 0.84 CNR2 (0.73) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL20840229 0.84 CNR2 (1.00) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL5015412 0.81 CNR2 (0.50) CNR2CNR1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012036383-A3 USE OF A PROTEIN TYROSINE KINASE INHIBITOR FOR INDUCING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO CARDIOGENIC CELLS 파미셀 주식회사 (KR) 2012-05-10 — — WO disclosed
EP-1927587-B1 Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof INT FLAVORS & FRAGRANCES INC (US) 2011-12-07 — — EP disclosed
EP-1927587-A2 Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof INTERNATIONAL FLAVORS & FRAGRANCES, INC. (US) 2008-06-04 — — EP disclosed
US-7329767-B2 Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2008-02-12 — — US disclosed
US-7329767-B2 Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2008-02-12 — — US disclosed
US-7329767-B2 Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2008-02-12 — — US disclosed
US-20050075368-A1 Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof INTERNATIONAL FLAVORS & FRAGRANCES INC.WW 2005-04-07 — — US disclosed
EP-1520850-A2 Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2005-04-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075368-A1 Conjugated dienamides, methods of production thereof, compositions containing same and uses thereof TAS2R41, TAS2R42, TAS2R14 CNR2 1265/4885CNR1 1556/4885ALDH1A1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback